Thymosin β4 (human, mouse, rat, porcine, bovine) (acetate) (Synonyms: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-NH2) |
| رقم الكتالوجGC45750 |
An actin-sequestering peptide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Thymosin β4 is an actin-sequestering peptide that has wound healing and anti-inflammatory activities.1,2,3 It regulates cytoskeletal rearrangement by binding to actin (Kds = 0.7 and 2.1 μM for human platelets and rabbit muscle, respectively) and inhibiting the polymerization of actin monomers.1 Thymosin β4 increases in vitro migration of human umbilical vein endothelial cells (HUVECs), keratinocytes, and coronary artery endothelial cells, but not fibroblasts, actin smooth muscle cells, neutrophils, monocytes, or HT-1080 fibrosarcoma cells, when used at concentrations ranging from 0.001 to 1 μg/ml.2,4 It increases gap closure and reduces wound width in a rat full-thickness cutaneous wound model when administered at a dose of 60 μg.2 Thymosin β4 (1 μg/ml) inhibits TNF-α-induced NF-•B phosphorylation and nuclear translocation in immortalized human corneal epithelial cells and decreases the expression of chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL2, matrix metalloproteinase-9 (MMP-9), and MMP-2 in the cornea in a mouse model of sodium hydroxide-induced corneal injury when administered at a dose of 5 μg.3
|1. Weber, A., Nachmias, V.T., Pennise, C.R., et al. Interaction of thymosin β4 with muscle and platelet actin: Implications for actin sequestration in resting platelets. Biochemistry 31(27), 6179-6185 (1992).|2. Malinda, K.M., Sidhu, G.S., Mani, H., et al. Thymosin β4 accelerates wound healing. J. Invest. Dermatol. 113(3), 364-368 (1999).|3. Sosne, G., Qiu, P., Christopherson, P.L., et al. Thymosin beta 4 suppression of corneal NFκB: A potential anti-inflammatory pathway. Exp. Eye Res. 84(4), 663-669 (2007).|4. Malinda, K.M., Goldstein, A.L., and Kleinman, H.K. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 11(6), 474-481 (1997).
| Cas No. | N/A | SDF | |
| المرادفات | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-NH2 | ||
| Canonical SMILES | N/A | ||
| Formula | C212H350N56O78S.XCF3CO2H | M.Wt | 4963.4 |
| الذوبان | PBS (pH 7.2): 10mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2015 mL | 1.0074 mL | 2.0147 mL |
| 5 mM | 0.0403 mL | 0.2015 mL | 0.4029 mL |
| 10 mM | 0.0201 mL | 0.1007 mL | 0.2015 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *